Want to take quizzes and track your credits?
Is an individualized biomechanical footwear therapy effective for reducing knee pain in people with knee osteoarthritis?
In this randomized clinical trial that included 220 participants with knee pain due to knee osteoarthritis, treatment with an individualized biomechanical footwear therapy compared with control footwear resulted in a lower Western Ontario and McMaster Universities Osteoarthritis Index pain subscore (range, 0-10) after 24 weeks of follow-up (1.3 vs 2.6, respectively), a difference that was statistically significant.
Although use of biomechanical footwear compared with control footwear resulted in an improvement in knee pain at 24 weeks of follow-up that was statistically significant, the difference was of uncertain clinical importance, and further research is needed to assess long-term efficacy and safety.
Individually calibrated biomechanical footwear therapy may improve pain and physical function in people with symptomatic knee osteoarthritis, but the benefits of this therapy are unclear.
To assess the effect of a biomechanical footwear therapy vs control footwear over 24 weeks of follow-up.
Design, Setting, and Participants
Randomized clinical trial conducted at a Swiss university hospital. Participants (N = 220) with symptomatic, radiologically confirmed knee osteoarthritis were recruited between April 20, 2015, and January 10, 2017. The last participant visit occurred on August 15, 2017.
Participants were randomized to biomechanical footwear involving shoes with individually adjustable external convex pods attached to the outsole (n = 111) or to control footwear (n = 109) that had visible outsole pods that were not adjustable and did not create a convex walking surface.
Main Outcomes and Measures
The primary outcome was knee pain at 24 weeks of follow-up assessed with the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain subscore standardized to range from 0 (no symptoms) to 10 (extreme symptoms). The secondary outcomes included WOMAC physical function and stiffness subscores and the WOMAC global score, all ranging from 0 (no symptoms) to 10 (extreme symptoms) at 24 weeks of follow-up, and serious adverse events.
Among the 220 randomized participants (mean age, 65.2 years [SD, 9.3 years]; 104 women [47.3%]), 219 received the allocated treatment and 213 (96.8%) completed follow-up. At 24 weeks of follow-up, the mean standardized WOMAC pain subscore improved from 4.3 to 1.3 in the biomechanical footwear group and from 4.0 to 2.6 in the control footwear group (between-group difference in scores at 24 weeks of follow-up, −1.3 [95% CI, −1.8 to −0.9]; P < .001). The results were consistent for WOMAC physical function subscore (between-group difference, −1.1 [95% CI, −1.5 to −0.7]), WOMAC stiffness subscore (between-group difference, −1.4 [95% CI, −1.9 to −0.9]), and WOMAC global score (between-group difference, −1.2 [95% CI, −1.6 to −0.8]) at 24 weeks of follow-up. Three serious adverse events occurred in the biomechanical footwear group compared with 9 in the control footwear group (2.7% vs 8.3%, respectively); none were related to treatment.
Conclusions and Relevance
Among participants with knee pain from osteoarthritis, use of biomechanical footwear compared with control footwear resulted in an improvement in pain at 24 weeks of follow-up that was statistically significant but of uncertain clinical importance. Further research would be needed to assess long-term efficacy and safety, as well as replication, before reaching conclusions about the clinical value of this device.
ClinicalTrials.gov Identifier: NCT02363712
Sign in to take quiz and track your certificates
JN Learning™ is the home for CME and MOC from the JAMA Network. Search by specialty or US state and earn AMA PRA Category 1 CME Credit™ from articles, audio, Clinical Challenges and more. Learn more about CME/MOC
CME Disclosure Statement: Unless noted, all individuals in control of content reported no relevant financial relationships. If applicable, all relevant financial relationships have been mitigated.
Corresponding Author: Peter Jüni MD, Applied Health Research Centre, Li Ka Shing Knowledge Institute, St Michael’s Hospital, 250 Yonge St, Toronto, ON M5B 2L7, Canada (firstname.lastname@example.org).
Accepted for Publication: March 3, 2020.
Author Contributions: Drs Reichenbach and Jüni had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.
Concept and design: Reichenbach, Felson, da Costa, Jones, Jüni.
Acquisition, analysis, or interpretation of data: Reichenbach, Felson, Hincapié, Heldner, Bütikofer, Lenz, da Costa, Bonel, Hawker, Jüni.
Drafting of the manuscript: Reichenbach, Felson, Hincapié, Jüni.
Critical revision of the manuscript for important intellectual content: Reichenbach, Hincapié, Heldner, Bütikofer, Lenz, da Costa, Bonel, Jones, Hawker, Jüni.
Statistical analysis: Bütikofer, Lenz, da Costa, Jüni.
Obtained funding: Jüni.
Administrative, technical, or material support: Felson, Heldner, da Costa, Jones, Jüni.
Supervision: Reichenbach, Felson, Bonel, Jüni.
Conflict of Interest Disclosures: Dr Jüni reported receiving grants from AstraZeneca, Biotronik, Biosensors, St Jude Medical, the Medicines Company, and the Canadian Institutes of Health Research; receiving honoraria from Amgen and Fresenius paid directly to his institution for participation on advisory boards; and serving as an unpaid member on steering committees for cardiovascular trials funded by AstraZeneca, Biotronik, Biosensors, St Jude Medical, and the Medicines Company. No other disclosures were reported.
Funding/Support: The trial was sponsored by Bern University Hospital and coordinated by CTU Bern, the University of Bern’s clinical trials unit. The trial was funded by the Mäxi Foundation. Dr Jüni is a tier 1 Canadian research chair in clinical epidemiology of chronic diseases; this research was completed, in part, with funding from the Canada Research Chairs Programme. Apos Medical Assets provided the biomechanical footwear system and the control footwear, and provided the technicians trained to install and calibrate the external pods on the biomechanical footwear without charge.
Role of the Funder/Sponsor: The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
Data Sharing Statement: See Supplement 4.
Additional Contributions: We thank the participants who participated in this trial. We acknowledge Avi Elbaz, MD, and Amit Mor, MD, for their contributions in the development of the control footwear; both were paid members of the board of AposTherapy Israel. We thank Madeleine Dähler and Zina Heg, MSc, for their contributions to data collection. At the time of data collection, both were paid staff members at CTU Bern and their salaries were funded by the Mäxi Foundation.
You currently have no searches saved.
You currently have no courses saved.